| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.2% | -94% | $79,128 | -$4,203,671 | 65,940 | -98% | T. Rowe Price Associates, Inc. | 31 Jan 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 400 shares of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS). This represents 0% of the company’s total 34,723,329 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 400 | $508 | -$17,871,868 | $1.27 | 1 |
| 2025 Q2 | 15,960,828 | $17,875,835 | -$2,104,201 | $1.12 | 66 |
| 2025 Q1 | 17,818,423 | $20,489,841 | -$7,726,102 | $1.15 | 78 |
| 2024 Q4 | 21,665,346 | $132,375,397 | -$11,575,882 | $6.11 | 80 |
| 2024 Q3 | 21,552,420 | $356,554,991 | -$28,738,996 | $16.54 | 72 |
| 2024 Q2 | 22,262,648 | $152,946,169 | -$7,201,124 | $6.87 | 82 |
| 2024 Q1 | 22,451,623 | $216,658,469 | +$8,694,626 | $9.65 | 67 |
| 2023 Q4 | 21,875,843 | $181,788,738 | -$5,233,058 | $8.31 | 70 |
| 2023 Q3 | 22,309,395 | $186,282,610 | +$4,170,162 | $8.35 | 76 |
| 2023 Q2 | 21,766,620 | $200,903,618 | +$35,209,839 | $9.23 | 75 |
| 2023 Q1 | 17,746,654 | $243,635,299 | -$3,025,252 | $13.74 | 71 |
| 2022 Q4 | 17,970,063 | $305,635,577 | +$820,913 | $17.01 | 76 |
| 2022 Q3 | 16,840,830 | $382,706,815 | -$8,175,678 | $22.74 | 84 |
| 2022 Q2 | 17,495,659 | $315,458,489 | -$21,884,151 | $18.03 | 87 |
| 2022 Q1 | 17,420,376 | $465,615,522 | +$11,163,137 | $26.73 | 88 |
| 2021 Q4 | 16,902,926 | $495,757,399 | +$6,401,077 | $29.33 | 79 |
| 2021 Q3 | 16,889,120 | $1,110,632,705 | +$20,009,554 | $65.76 | 103 |
| 2021 Q2 | 16,328,758 | $1,357,993,485 | -$126,262,925 | $83.20 | 102 |
| 2021 Q1 | 17,986,386 | $1,380,234,693 | +$66,574,074 | $76.69 | 108 |
| 2020 Q4 | 15,954,413 | $1,408,600,264 | +$177,474,623 | $88.29 | 106 |
| 2020 Q3 | 14,532,856 | $1,072,684,675 | +$48,365,373 | $73.81 | 89 |
| 2020 Q2 | 13,878,230 | $1,013,074,077 | +$45,598,473 | $73.00 | 78 |
| 2020 Q1 | 13,268,896 | $741,900,915 | +$66,543,311 | $56.15 | 60 |
| 2019 Q4 | 12,196,527 | $463,251,136 | +$92,385,423 | $38.16 | 50 |
| 2019 Q3 | 10,035,118 | $178,125,000 | +$178,125,044 | $17.75 | 33 |